ArticleScientific reports2022
A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- A systematic review on the culture methods and applications of 3D tumoroids for cancer research and personalized medicine.Cellular oncology (Dordrecht, Netherlands) · 2025Pooled it
- Animal organoids as models for integrated One Health research.One health (Amsterdam, Netherlands) · 2026Review
- p53 in Canine Mammary Tumors: From Molecular Pathogenesis to Biomarker Applications and Comparative Oncology.Veterinary sciences · 2026Review
- AKR1B1 promotes canine mammary tumorigenesis via activation of PI3K/AKT signaling and acts as a serum biomarker.Scientific reports · 2026Article
- Comparative Digital Estrogen Receptor Alpha (ERα) Expression Analysis in Benign and Malignant Prostate Tissue of Men and Dogs.The Prostate · 2026Article
- The oncogenome of the domestic cat.Science (New York, N.Y.) · 2026Article
- Comparative analysis of zebrafish, organoid, and organ-on-chip models in breast cancer research.Biotechnology notes (Amsterdam, Netherlands) · 2026Review
- From comparative oncology to AI-enabled precision medicine: translational biomodels for triple-negative breast cancer.Frontiers in oncology · 2026Article
- Perspective: from pathogenesis to treatment in veterinary science through organoid disease modelling.Frontiers in veterinary science · 2026Article
- Pet owners' perspectives on veterinary biobanking in Latvia: Awareness, motivations, ethical concerns, and willingness to participate.Veterinary world · 2025Article
- Advancing In Vitro Tools for Oncologic Research in Cats and Dogs.Veterinary sciences · 2025Review
- CEBPD regulates CD47 and MAP4K4 via chromatin accessibility in canine mammary tumor monocytes.Scientific reports · 2025Article
- Integration of Organoids With CRISPR Screens: A Narrative Review.Biology of the cell · 2025Review
- Individualized Pooled CRISPR/Cas9 Screenings Identify CDK2 as a Druggable Vulnerability in a Canine Mammary Carcinoma Patient.Veterinary sciences · 2025Article
- Canine mammary tumors as a promising adjunct preclinical model for human breast cancer research: similarities, opportunities, and challenges.Archives of pharmacal research · 2025Review
- Canine organoids: state-of-the-art, translation potential for human medicine and plea for standardization.Frontiers in veterinary science · 2025Review
- Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future.Veterinary sciences · 2024Review
- Three-Dimensional Cultivation a Valuable Tool for Modelling Canine Mammary Gland Tumour Behaviour In Vitro.Cells · 2024Review
- Anti-cancer effects of DHP107 on canine mammary gland cancer examined through in-vitro and in-vivo mouse xenograft models.BMC veterinary research · 2024Article
- Leveraging the predictive power of 3D organoids in dogs to develop new treatments for man and man's best friend.BMC biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
Abstract
Mammary tumors in dogs hold great potential as naturally occurring breast cancer models in translational oncology, as they share the same environmental risk factors, key histological features, hormone receptor expression patterns, prognostic factors, and genetic characteristics as their human counterparts. We aimed to develop in vitro tools that allow functional analysis of canine mammary tumors (CMT), as we have a poor understanding of the underlying biology that drives the growth of these heterogeneous tumors. We established the long-term culture of 24 organoid lines from 16 dogs, including organoids derived from normal mammary epithelium or benign lesions. CMT organoids recapitulated key morphological and immunohistological features of the primary tissue from which they were derived, including hormone receptor status. Furthermore, genetic characteristics (driver gene mutations, DNA copy number variations, and single-nucleotide variants) were conserved within tumor-organoid pairs. We show how CMT organoids are a suitable model for in vitro drug assays and can be used to investigate whether specific mutations predict therapy outcomes. Specifically, certain CMT subtypes, such as PIK3CA mutated, estrogen receptor-positive simple carcinomas, can be valuable in setting up a preclinical model highly relevant to human breast cancer research. In addition, we could genetically modify the CMT organoids and use them to perform pooled CRISPR/Cas9 screening, where library representation was accurately maintained. In summary, we present a robust 3D in vitro preclinical model that can be used in translational research, where organoids from normal, benign as well as malignant mammary tissues can be propagated from the same animal to study tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.